Comprehensive Cellular Senescence Evaluation to Aid Targeted Therapies

Area of Science:

• Oncology
• Cancer Biology
• Drug Discovery

Background:

• Drug resistance to single-agent targeted therapies is a significant challenge in cancer treatment.
• Cellular senescence, inducible by FDA-approved drugs, presents unique vulnerabilities and molecular signatures.
• Limited research exists on combining senescence-inducing agents with targeted therapies.

Purpose of the Study:

• To comprehensively evaluate cellular senescence states in tumors and their association with targeted drug responses.
• To investigate the therapeutic potential of combining senescence-inducing agents with targeted therapies.
• To identify novel vulnerabilities associated with cellular senescence for targeted cancer therapy.

Main Methods:

• Analysis of ~10,000 tumor samples from The Cancer Genome Atlas (TCGA) using 7 senescence-associated gene sets.
• Quantification of cellular senescence scores and examination of their correlation with targeted drug responses.
• Experimental validation using lung cancer cells treated with etoposide to induce senescence, followed by exposure to erlotinib and dasatinib.

Main Results:

• Higher cellular senescence scores in tumors correlated with increased sensitivity to targeted drugs.
• Etoposide-induced senescence sensitized lung cancer cells to targeted drugs erlotinib and dasatinib.
• Identification of genes whose dependencies are linked to senescence status across ~1,000 cancer cell lines.

Conclusions:

• Cellular senescence can enhance sensitivity to targeted cancer therapies.
• Combining senescence-inducing agents with targeted therapies holds promise for improving treatment outcomes, particularly in lung cancer.
• Cellular senescence creates exploitable vulnerabilities in cancer cells, opening new avenues for targeted therapeutic strategies.